Please login to the form below

Vifor Pharma

This page shows the latest Vifor Pharma news and features for those working in and with pharma, biotech and healthcare.

ChemoCentryx surges on phase 3 vasculitis study

The positive results set up regulatory filings in both the US and Europe next year, according to ChemoCentryx, which has licensed ex-US rights to Switzerland’s Vifor Fresenius Medical Care ... Renal Pharma (VFMCRP), a joint venture between Vifor

Latest news

Evotec and Vifor announce joint venture for kidney disease treatments

Both companies will split the clinical and commercial costs equally. Evotec and Vifor Pharma have launched a joint venture focused on the research and development of nephrology therapeutics for the treatment ... We are excited to be entering into this
Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.
AZ gets US approval for Veltassa rival Lokelma

AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... AZ acquired Lokelma via the $2.7bn acquisition of ZS Pharma three years ago
AZ finally gets EU nod for Veltassa rival Lokelma

challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... delaying approval and giving Vifor time to consolidate its position in the market.
Novartis and Bayer among backers for European big data project

Novartis, Bayer, Servier and Vifor Pharma are among those participating in BigData@Heart, a five-year, 19m project supported by the Innovative Medicines Initiative (IMI). ... Digital inspiration for pharma on mobile, social media, strategy, best practice,

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Other pharma companies divesting assets this month include Janssen/J&J and Sanofi. ... In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the
Deal Watch July 2016

Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Galenica, the Swiss healthcare company that is preparing itself for a split into two parts, Vifor Pharma (healthcare product development, manufacturing and
Deal Watch May 2016

The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D prohormone treatment] from OPKO paying ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Hansa Medical poaches Vifor Pharma’s CEO

Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
Swiss biotech Inositec appoints new chief medical officer

Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at
Galenica Group strengthens management team

Appoints Stefan Schulze, Felix Burkhard and Jörg Kneubühler. Stefan Schulze has been appointed as chief operating officer and president of the executive committee of Vifor Pharma, part of the Switzerland-based ... We opted for these variant because of
Lupin appoints Thierry Volle president for EMEA

He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... He joins the firm from Vifor Pharma, where he was the head of EU and International
Verona names David Ebsworth as non-executive chairman

He joins from Vifor Pharma. Verona Pharma has appointed Dr David Ebsworth as its non-executive chairman of the board of directors. ... He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

EPG Health

Mylan, Novartis, Orphan Europe, Philips, Pfizer, Roche, Sanofi, Takeda, UCB, Uriach, Vifor Pharma. ... See how three pharma companies supported the provision of virtual and on-demand scientific meetings for HCPs during COVID-19.
IGNIFI

Kyowa Kirin. Sobi. Theramex. Veriton Pharma. Vifor Pharma. ... I’m delighted you’re on my team.". BRAND MANAGER. Global Top 20 Pharma Company. -.